Cisplatin- based chemotherapy of epithelial ovarian cancer

✍ Scribed by Howard D. Homesley

• Publisher: John Wiley and Sons
• Year: 1989
• Tongue: English
• Weight: 500 KB
• Volume: 42
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.2930420506

✦ Synopsis

The current International Federation of Gynecology and Obstetrics (FIGO) staging system, independent prognostic factors, and review of the Gynecologic Oncology Group (GOG) studies in epithelial ovarian carcinoma are presented. With this background, approaches using cisplatinbased regimens in ovarian carcinoma trials are outlined. A short threecourse cycle of cisplatin plus cyclophosphamide is currently being compared with intraperitoneal phosphorus 32 in high-risk stage 1-11 patients. In optimal stage IT1 patients, cisplatin plus cyclophosphamide without doxorubicin in a recent GOG study was as effective as all three drugs.

In suboptimal stage I11 patients, a current dose-intensity study is comparing 100 mg/m2 cisplatin plus 1 g/m2 cyclophosphamide for four courses to the previously studied eight courses of 50 mg/m2 cisplatin and 500 mg/m2 cyclophosphamide. Trials are also under way to determine the utility of intraperitoneal cisplatin in a phase I11 study of optimal stage I11 as firstline therapy and another study is active for second-line salvage.